--- title: "Altamira Therapeutics (CYTOF) news: reverse split" url: "https://aibio.space/companies/altamira-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CYTOF reverse split news: Altamira Therapeutics moves from Nasdaq to OTCQB after panel decision. Altamira Therapeutics Ltd. (OTC: CYTOF), Bermuda." --- CYTOF Altamira Therapeutics Ltd. OTC · Bermuda # Altamira Therapeutics (CYTOF) news CYTOF reverse split news Listings · 2026-02-27 ## [Altamira Therapeutics files Form 15 to end SEC reporting duties](https://aibio.space/news/altamira-therapeutics-files-form-15-end-sec-reporting-duties/) Altamira Therapeutics filed a Form 15 dated February 27, 2026, to terminate its registration or suspend its duty to file reports with the SEC. The form lists 48 holders of record, and the company's last business description, from April 2025, still calls its lead programs preclinical. ## Latest Altamira Therapeutics news 1. 2024-12-20 Listings [Altamira Therapeutics moves from Nasdaq to OTCQB after panel decision](https://aibio.space/news/altamira-therapeutics-moves-nasdaq-otcqb-after-panel-decision/) The Nasdaq Hearings Panel denied the company's request to stay listed over the $1.00 minimum bid price rule. Shares are to trade as CYTOF, and the company says it plans no reverse stock split. ## Altamira Therapeutics at a glance - **Ticker**: CYTOF - **Listing**: OTC - **Country**: Bermuda ### Related companies - [Tiziana Life Sciences](https://aibio.space/companies/tiziana-life-sciences/) NASDAQ: TLSA ### Also on OTC - [Modern Mobility Aids](https://aibio.space/companies/modern-mobility-aids/) MDRM - [PetVivo Holdings](https://aibio.space/companies/petvivo/) PETV - [EHOUSE GLOBAL INC](https://aibio.space/companies/ehouse-global/) EHOS - [Halberd](https://aibio.space/companies/halberd/) HALB - [ITonis](https://aibio.space/companies/itonis/) ITNS - [Bio-Path Holdings](https://aibio.space/companies/bio-path/) BPTH ## What Altamira Therapeutics does Altamira Therapeutics Ltd. is a preclinical-stage biopharmaceutical company incorporated in Bermuda. It develops and supplies peptide-based nanoparticle technologies for RNA delivery to extrahepatic tissues through its xPhore platform. The platform is intended for oligonucleotides such as short interfering RNA (OligoPhore), linear messenger RNA (SemaPhore) and circular mRNA (CycloPhore), and is to be made available to pharma or biotech companies through out-licensing. Its two flagship siRNA programs use OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. In 2023 the company spun off a 51% stake in Altamira Medica AG, which manufactures and markets Bentrio, an OTC nasal spray for allergic rhinitis, and it continues to hold a 49% stake in the Bentrio business. The company has announced its intention to partner or divest legacy assets, including AM-125, a nasal spray for vertigo that is post Phase 2, and its tinnitus and hearing loss programs. Its goal is to become a leading biomedical company focused on RNA delivery technology. | Product or program | What it is | Stage | |---|---|---| | AM-401 | OligoPhore siRNA program for KRAS driven cancer | preclinical development beyond in vivo proof of concept | | AM-411 | OligoPhore siRNA program for rheumatoid arthritis | preclinical development beyond in vivo proof of concept | | AM-125 | Nasal spray for vertigo, legacy asset to be partnered or divested | post Phase 2 | | Bentrio | OTC nasal spray for allergic rhinitis, marketed by Altamira Medica AG | | Summarised from the company's [20-F filed Apr 30, 2025](https://www.sec.gov/Archives/edgar/data/1601936/000121390025037199/ea0237996-20f_altamira.htm). ## Altamira Therapeutics annual financials | Line | FY2020 | FY2019 | |---|---|---| | Research and development | [CHF 2.9 million](https://www.sec.gov/Archives/edgar/data/1601936/000121390021018959/) | [CHF 3.3 million](https://www.sec.gov/Archives/edgar/data/1601936/000121390021018959/) | | Net income (loss) | [-CHF 8.2 million](https://www.sec.gov/Archives/edgar/data/1601936/000121390021018959/) | [-CHF 6.6 million](https://www.sec.gov/Archives/edgar/data/1601936/000121390021018959/) | Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Altamira Therapeutics Did Altamira Therapeutics do a reverse stock split? Our latest story on this, dated Dec 20, 2024: "Altamira Therapeutics moves from Nasdaq to OTCQB after panel decision". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/altamira-therapeutics-moves-nasdaq-otcqb-after-panel-decision/). What is the ticker symbol of Altamira Therapeutics? Altamira Therapeutics Ltd. trades under the ticker CYTOF on OTC. Where is Altamira Therapeutics listed? Altamira Therapeutics Ltd. is listed on OTC. What is the SEC CIK of Altamira Therapeutics? The SEC Central Index Key (CIK) for Altamira Therapeutics Ltd. is 1601936. Its filings are on SEC EDGAR. How many shares does Altamira Therapeutics have outstanding? 4,662,080 shares as of 2024-12-31, per the cover page of its 20-F filed 2025-04-30. Which country or territory is Altamira Therapeutics listed under? Our directory records Altamira Therapeutics Ltd. under Bermuda. What does Altamira Therapeutics do? Our directory classifies Altamira Therapeutics Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Altamira Therapeutics? The ISIN recorded for Altamira Therapeutics Ltd. is BMG0360L1349. Does aibio.space cover Altamira Therapeutics? aibio.space lists Altamira Therapeutics Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Altamira Therapeutics incorporated? SEC records list its state or country of incorporation as D0. What does Altamira Therapeutics develop? Altamira Therapeutics Ltd. is a preclinical-stage biopharmaceutical company incorporated in Bermuda. It develops and supplies peptide-based nanoparticle technologies for RNA delivery to extrahepatic tissues through its xPhore platform. What is AM-401 from Altamira Therapeutics? AM-401: OligoPhore siRNA program for KRAS driven cancer Stage: preclinical development beyond in vivo proof of concept. What is AM-411 from Altamira Therapeutics? AM-411: OligoPhore siRNA program for rheumatoid arthritis Stage: preclinical development beyond in vivo proof of concept. What is the latest Altamira Therapeutics (CYTOF) stock news? Our latest story on Altamira Therapeutics, dated Feb 27, 2026: "Altamira Therapeutics files Form 15 to end SEC reporting duties". Altamira Therapeutics filed a Form 15 dated February 27, 2026, to terminate its registration or suspend its duty to file reports with the SEC. The form lists 48 holders of record, and the company's last business description, from April 2025, still calls its lead programs preclinical. [Source](https://aibio.space/news/altamira-therapeutics-files-form-15-end-sec-reporting-duties/). Is Altamira Therapeutics a smaller reporting company? SEC records list Altamira Therapeutics Ltd.'s filer category as: Non-accelerated filer. ## Investor discussion: Altamira Therapeutics Members talk about Altamira Therapeutics (CYTOF). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Altamira Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-02-27 Listings Filed to end its SEC reporting. SEC Form 15-12G. [Source](https://www.sec.gov/Archives/edgar/data/1601936/000121390026021580/eaf1512g-1512g_altamira.htm) 2. 2025-06-17 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1601936/000135445725000544/xslF25X02/primary_doc.xml) 3. 2025-03-10 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1601936/000121390025022236/ea0233793-6k_altamira.htm) 4. 2024-12-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1601936/000121390024110771/ea022551401ex99-1_altamira.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:CYTOF on TradingView](https://www.tradingview.com/symbols/OTC-CYTOF/). ## SEC filings and registration - **SEC name**: Altamira Therapeutics Ltd. - **CIK**: 1601936 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CYTOF (OTC) - **State or country of incorporation**: D0 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: CLARENDON HOUSE, HAMILTON HM 11, Bermuda, 00000 - **Phone**: 41 (0) 41 729 71 94 - **Shares outstanding**: 4,662,080 as of 2024-12-31 (20-F filed 2025-04-30) - **Former names**: Auris Medical Holding Ltd.; Auris Medical Holding AG; Auris Medical AG ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1601936/000121390025082071/ea0254753-6k_altamira.htm) filed 2025-08-29 - [6-K](https://www.sec.gov/Archives/edgar/data/1601936/000121390025053451/ea0245271-6k_altamira.htm) filed 2025-06-11 - [6-K](https://www.sec.gov/Archives/edgar/data/1601936/000121390025041560/ea0241380-6k_altamira.htm) filed 2025-05-09 - [20-F](https://www.sec.gov/Archives/edgar/data/1601936/000121390025037199/ea0237996-20f_altamira.htm) filed 2025-04-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1601936/000121390025037097/ea0240160-6k_altamira.htm) filed 2025-04-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1601936/000121390025022236/ea0233793-6k_altamira.htm) filed 2025-03-10 - [6-K](https://www.sec.gov/Archives/edgar/data/1601936/000121390024110771/ea0225514-6k_altamira.htm) filed 2024-12-20 - [6-K](https://www.sec.gov/Archives/edgar/data/1601936/000121390024085537/ea0216654-6k_altamira.htm) filed 2024-10-04 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001601936), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Altamira Therapeutics Ltd. is a public biotech or pharmaceutical company listed on OTC under the ticker CYTOF, recorded under Bermuda. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Altamira Therapeutics Ltd. - **Ticker**: CYTOF - **Listing**: OTC - **Country or territory**: Bermuda - **Business scope**: Biotechnology - **ISIN**: BMG0360L1349 - **Last quote in directory**: 2026-10-20 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-CYTOF/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/altamira-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Altamira Therapeutics (CYTOF) news: reverse split", 2026-10-31, https://aibio.space/companies/altamira-therapeutics/